[go: up one dir, main page]

CL2019003801A1 - Nuevas formulaciones orales de belinostato. - Google Patents

Nuevas formulaciones orales de belinostato.

Info

Publication number
CL2019003801A1
CL2019003801A1 CL2019003801A CL2019003801A CL2019003801A1 CL 2019003801 A1 CL2019003801 A1 CL 2019003801A1 CL 2019003801 A CL2019003801 A CL 2019003801A CL 2019003801 A CL2019003801 A CL 2019003801A CL 2019003801 A1 CL2019003801 A1 CL 2019003801A1
Authority
CL
Chile
Prior art keywords
belinostate
oral formulations
new oral
formulations
new
Prior art date
Application number
CL2019003801A
Other languages
English (en)
Inventor
Perrine Pivette
Caroline Lemarchand
Ian Yates
Corey Bloom
Original Assignee
Onxeo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo filed Critical Onxeo
Publication of CL2019003801A1 publication Critical patent/CL2019003801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A NUEVAS FORMULACIONES DE BELINOSTAT ADECUADAS PARA ADMINISTRACIÓN ORAL, SU PROCESO DE PREPARACIÓN, LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHAS FORMULACIONES Y SUS USOS.
CL2019003801A 2017-06-30 2019-12-20 Nuevas formulaciones orales de belinostato. CL2019003801A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527684P 2017-06-30 2017-06-30
EP17305853 2017-07-03

Publications (1)

Publication Number Publication Date
CL2019003801A1 true CL2019003801A1 (es) 2020-09-11

Family

ID=62816549

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003801A CL2019003801A1 (es) 2017-06-30 2019-12-20 Nuevas formulaciones orales de belinostato.

Country Status (24)

Country Link
US (1) US11266614B2 (es)
EP (1) EP3644970B8 (es)
JP (1) JP7247122B2 (es)
CN (1) CN110996913A (es)
AU (1) AU2018294561B2 (es)
BR (1) BR112019028088A8 (es)
CA (1) CA3067723A1 (es)
CL (1) CL2019003801A1 (es)
CO (1) CO2019014831A2 (es)
CY (1) CY1125762T1 (es)
DK (1) DK3644970T3 (es)
EC (1) ECSP19091293A (es)
ES (1) ES2909583T3 (es)
HR (1) HRP20220309T1 (es)
HU (1) HUE057999T2 (es)
IL (1) IL271658B2 (es)
LT (1) LT3644970T (es)
MX (1) MX393915B (es)
PE (1) PE20241993A1 (es)
PL (1) PL3644970T3 (es)
RS (1) RS63046B1 (es)
SI (1) SI3644970T1 (es)
SM (1) SMT202200191T1 (es)
ZA (1) ZA201908532B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
WO2021188695A1 (en) * 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517690A (ja) * 2002-02-01 2005-06-16 ファイザー・プロダクツ・インク 固体薬物分散物を含有する即時放出剤形
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
CN102579417B (zh) * 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
JP2007045788A (ja) * 2005-08-12 2007-02-22 Kenjiro Koga グリチルリチン酸高濃度水溶液の調製法
EP1957056A2 (en) * 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2011064663A1 (en) * 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
US9114170B2 (en) * 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
CA2947593A1 (en) * 2014-05-02 2015-11-05 Oncoethix Gmbh Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
CA2955747A1 (en) * 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
US11439643B2 (en) * 2015-06-16 2022-09-13 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma
JP2017095428A (ja) * 2015-11-27 2017-06-01 国立大学法人神戸大学 脂質代謝改善剤
WO2018029699A1 (en) * 2016-08-11 2018-02-15 Msn Research & Development Center Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof

Also Published As

Publication number Publication date
PE20241993A1 (es) 2024-09-27
BR112019028088A8 (pt) 2022-11-08
EP3644970B8 (en) 2022-03-16
CO2019014831A2 (es) 2020-04-24
US20200155485A1 (en) 2020-05-21
ECSP19091293A (es) 2020-05-29
RS63046B1 (sr) 2022-04-29
US11266614B2 (en) 2022-03-08
EP3644970B1 (en) 2022-02-09
BR112019028088A2 (pt) 2020-07-28
JP2020525499A (ja) 2020-08-27
DK3644970T3 (da) 2022-03-14
IL271658B2 (en) 2023-09-01
HRP20220309T1 (hr) 2022-05-13
IL271658A (en) 2020-02-27
ZA201908532B (en) 2022-07-27
CN110996913A (zh) 2020-04-10
AU2018294561B2 (en) 2023-12-07
MX2019015869A (es) 2020-08-06
MX393915B (es) 2025-03-24
AU2018294561A1 (en) 2020-01-16
IL271658B1 (en) 2023-05-01
PL3644970T3 (pl) 2022-04-25
SMT202200191T1 (it) 2022-07-21
SI3644970T1 (sl) 2022-05-31
JP7247122B2 (ja) 2023-03-28
ES2909583T3 (es) 2022-05-09
EP3644970A1 (en) 2020-05-06
LT3644970T (lt) 2022-04-25
CA3067723A1 (en) 2019-01-03
CY1125762T1 (el) 2024-02-16
HUE057999T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2018000059A (es) Composiciones de insulina de rápida acción
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
CL2018001742A1 (es) Compuestos indolinones y sus usos en el tratamiento de enfermedades fibroticas.
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
PE20180039A1 (es) Piroglutamato de vortioxetina
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
CO2019000083A2 (es) Composiciones farmacéuticas
MX2020001954A (es) Composiciones para el cuidado bucal y sus usos.
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
BR112017009848A2 (pt) combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica.
UY38217A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona
MX376088B (es) Composición que comprende productos de abeja.